Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Spotlight on valsartan-sacubitril fixed-dose combination for heart failure: the evidence to date.

Vilela-Martin JF.

Drug Des Devel Ther. 2016 May 9;10:1627-39. doi: 10.2147/DDDT.S84782. eCollection 2016. Review.

2.

Electrocardiographic predictors of sudden and non-sudden cardiac death in patients with ischemic cardiomyopathy.

Al-Zaiti SS, Fallavollita JA, Canty JM Jr, Carey MG.

Heart Lung. 2014 Nov-Dec;43(6):527-33. doi: 10.1016/j.hrtlng.2014.05.008. Epub 2014 Jul 2.

3.

Psychometric properties of the Symptom Status Questionnaire-Heart Failure.

Heo S, Moser DK, Pressler SJ, Dunbar SB, Mudd-Martin G, Lennie TA.

J Cardiovasc Nurs. 2015 Mar-Apr;30(2):136-44. doi: 10.1097/JCN.0000000000000102.

4.

Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF).

McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau J, Shi VC, Solomon SD, Swedberg K, Zile MR; PARADIGM-HF Committees and Investigators.

Eur J Heart Fail. 2013 Sep;15(9):1062-73. doi: 10.1093/eurjhf/hft052. Epub 2013 Apr 5.

5.

Individual patient data meta-analysis of beta-blockers in heart failure: rationale and design.

Kotecha D, Manzano L, Altman DG, Krum H, Erdem G, Williams N, Flather MD; Beta-Blockers in Heart Failure Collaborative Group.

Syst Rev. 2013 Jan 18;2:7. doi: 10.1186/2046-4053-2-7.

6.

Adverse drug events and associated factors in heart failure therapy among the very elderly.

Sztramko R, Chau V, Wong R.

Can Geriatr J. 2011 Dec;14(4):79-92. doi: 10.5770/cgj.v14i4.19. Epub 2011 Dec 12.

7.

Explaining the increase in coronary heart disease mortality in Syria between 1996 and 2006.

Rastam S, Al Ali R, Maziak W, Mzayek F, Fouad FM, O'Flaherty M, Capewell S.

BMC Public Health. 2012 Sep 9;12:754. doi: 10.1186/1471-2458-12-754.

8.

Is heart rate reduction more important than target dose in chronic heart failure therapy with a beta-blocker?

Guo YF, An Y.

J Geriatr Cardiol. 2011 Dec;8(4):260-2. doi: 10.3724/SP.J.1263.2011.00260. No abstract available.

9.

Nebivolol: impact on cardiac and endothelial function and clinical utility.

Toblli JE, DiGennaro F, Giani JF, Dominici FP.

Vasc Health Risk Manag. 2012;8:151-60. doi: 10.2147/VHRM.S20669. Epub 2012 Mar 13. Review.

10.

The predicted impact of heart disease prevention and treatment initiatives on mortality in Lithuania, a middle-income country.

Kottke TE, Jancaityte L, Tamosiunas A, Grabauskas V.

Prev Chronic Dis. 2011 Nov;8(6):A139. Epub 2011 Oct 17.

12.

A self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly.

Ramsay EN, Roughead EE, Ewald B, Pratt NL, Ryan P.

BMC Med Res Methodol. 2011 Jul 18;11:106. doi: 10.1186/1471-2288-11-106.

13.

Targeting success in heart failure: evidence-based management.

Gruszczynski AB, Schuster B, Regier L, Jensen B.

Can Fam Physician. 2010 Dec;56(12):1313-7.

14.

Heart rate control with adrenergic blockade: clinical outcomes in cardiovascular medicine.

Feldman D, Elton TS, Menachemi DM, Wexler RK.

Vasc Health Risk Manag. 2010 Jun 1;6:387-97. Review.

15.

Trends and inequities in beta-blocker prescribing for heart failure.

Shah SM, Carey IM, DeWilde S, Richards N, Cook DG.

Br J Gen Pract. 2008 Dec;58(557):862-9. doi: 10.3399/bjgp08X376195.

16.
17.

Population impact of stricter adherence to recommendations for pharmacological and lifestyle interventions over one year in patients with coronary heart disease.

Gemmell I, Heller RF, McElduff P, Payne K, Butler G, Edwards R, Roland M, Durrington P.

J Epidemiol Community Health. 2005 Dec;59(12):1041-6.

18.

Association between adherence measurements of metoprolol and health care utilization in older patients with heart failure.

Tu W, Morris AB, Li J, Wu J, Young J, Brater DC, Murray MD.

Clin Pharmacol Ther. 2005 Mar;77(3):189-201.

Supplemental Content

Support Center